Oropharynx cancers caused by human papillomavirus (HPV) have risen dramatically over the years, superseding tobacco use and heavy drinking as the primary driver of new cases.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include an investigation into the efficacy of dexamethasone for dyspnea relief, a combination therapy for hairy cell leukemia, an analysis of RAS mutations and their prognostic value in acute myeloid leukemia (AML), a possible new combination therapy for basal-like breast cancer, and swallowing exercises to improve the quality of life for patients with head and neck cancer undergoing radiotherapy.
Sylvester Comprehensive Cancer Center researchers Lluis Morey, Ph.D., and Ramiro Verdun, Ph.D., have received a $1.8 million NIH R01 grant to study the epigenetic mechanisms that drive head and neck cancers.
Henry Ford Health + Michigan State University Health Sciences today announced its funding of five cancer research grants of up to $100,000 each. These five grants follow an initial wave of funding from the partnership, in which 18 pilot grants of up to $25,000 each were funded in May 2022.
Patients with squamous cell carcinoma of the head or neck were 93% less likely to die of any cause during the first three years after diagnosis if they ate a healthy diet high in nutrients found to deter chronic disease, researchers found in a recent study.
A new study finds that early postoperative CT scans and MRIs can help predict whether a free flap, used for reconstructive head and neck cancer surgery, will fail. The method carries around a 10-40% risk of wound complications, and researchers say the findings could allow surgeons to intervene earlier if the flap fails.
Researchers from Wake Forest University School of Medicine have discovered a possible new approach in treating solid tumors through the creation of a novel nanoparticle.
The warning signs of head and neck cancer can be easy to miss. But according to a Penn State Health physician, prevention is possible.
A new study from the University of Michigan Health Rogel Cancer Center finds circulating tumor DNA, or ctDNA, levels can predict as early as two weeks after starting treatment which patients are likely to have good outcomes. At the same time, specialized MRI and PET scans two weeks after starting chemoradiation also correlated with outcomes.
University of Delaware materials scientist Xinqiao Jia has received a combined $4.85 million in funding from the National Institutes of Health (NIH) for research to develop new approaches in tissue engineering. Jia and colleagues will explore ways to regenerate salivary glands damaged by radiation therapy for head and neck cancers. She also will focus on understanding what causes damage or scarring to vocal folds, the pliable tissue that enables our ability to talk.
A research team led by Penn Nursing’s Jie Deng, PhD, RN, OCN, FAAN, Associate Professor of Nursing in the Department of Biobehavioral Health Sciences, has been approved for a $3 million funding award by the Patient-Centered Outcomes Research Institute (PCORI) to study lymphedema management in head and neck cancer survivors.
Expanding its multidisciplinary teams of highly specialized experts uniquely focused on the management of head and neck cancers and cancer of the lung, pleura and mediastinum, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have welcomed Missak Haigentz, Jr., MD, as chief of Thoracic and Head and Neck Medical Oncology and clinical director for Oncology Integration.
Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the number one center for ear, nose, and throat care by U.S. News & World Report in its annual Best Hospitals listing. MSK has been consistently ranked among the top two cancer centers in the country for over 30 years.
Up to half of patients with head and neck squamous cell carcinoma will experience tumor recurrence or new tumors—tumors that often spread and are difficult to treat.
Computer scientists at the University of Illinois Chicago are developing a computational artificial intelligence system they hope will serve as a decision support tool for doctors prescribing treatment for head and neck cancer. The work is supported by a $2.8 million grant from the National Institutes of Health.
A multi-institutional team of researchers, led by UC San Diego School of Medicine and Moores Cancer Center, has identified both the genetic abnormalities that drive pre-cancer cells into becoming an invasive type of head and neck cancer and patients who are least likely to respond to immunotherapy.
In a study by Yale Cancer Center, researchers report on the discovery of a new role for STimulator of INterferon Genes or STING. STING has traditionally been implicated in the immune response to DNA damage, however, in this study, the focus is on STING’s role in the tumor DNA damage response.
Two University of Colorado Cancer Center researchers have received a five-year R01 Award for $497,893 per year from the National Institutes of Health (NIH) to study a potential new drug treatment for salivary gland cancer. The award is part of an inter-campus collaboration between Antonio Jimeno, MD, PhD, co-leader of the Developmental Therapeutics Program, and Tin Tin Su, PhD, co-leader of the Molecular and Cellular Oncology Program.
Cancer treatment is likely to affect every aspect of a patient’s life — their activities, relationships, eating habits, mental health, physical health and comfort, financial wellbeing. And when financial concerns weigh heavily on an individual who is in treatment for cancer, they can affect the outcome of that treatment. New research from Roswell Park Comprehensive Cancer Center provides the first evidence that a cancer patient’s level of financial worry as they begin treatment predicts how likely it is that their treatment will be successful.
A wide breadth of behaviors surrounding oral sex may affect the risk of oral HPV infection and of a virus-associated head and neck cancer that can be spread through this route, a new study led by researchers at the Johns Hopkins Kimmel Cancer Center suggests. These findings add nuance to the connection between oral sex and oropharyngeal cancer — tumors that occur in the mouth and throat — and could help inform research and public health efforts aimed at preventing this disease.
Retrospective research by Henry Ford otolaryngologists found telemedicine use disparity among head and neck cancer patients during start of COVID-19 pandemic.
Henry Ford Health System is the first in Michigan to offer the da Vinci SP® robotic surgery system, which requires only a single small incision for its surgical instruments and allows for greater control and access in narrow surgical spaces.
Mass Eye and Ear is proud to announce the successful conclusion of its historic campaign, “Bold Science. Life-Changing Cures.” which raised $252M from philanthropy to advance research to treat and cure diseases of vision, hearing, and the head and neck.
The campaign was led by co-chair Wyc Grousbeck, Boston Celtics CEO and Lead Owner and former Chairman of Mass Eye and Ear.
A new phase 2 clinical trial found the drug axitinib was able to extend the lives of patients with incurable head and neck cancer by several months, and also identified a subset of patients with a specific mutation for whom the drug is likely to work best.
Human papillomavirus (HPV) is the most common sexually transmitted infection and the cause of most cervical cancers, and some vaginal, penile, anal and oral cancers. The HPV vaccine has proven effective in preventing infection and six types of HPV-attributable cancers. …
Researchers at UC San Diego School of Medicine and Moores Cancer Center report that an investigational drug candidate called tipifarnib showed promise in treating key recurring mutation in head and neck cancers.
As we observe World Head and Neck Cancer Day 2020 (July 27), nationally known expert Tom Thomas, MD, MPH, has set out to clear up misunderstandings about how one type of head and neck cancer is related to human papillomavirus (HPV), which has historically been thought of primarily as a cause of cervical cancer. Dr. Thomas is medical director, Head and Neck Reconstructive Surgery and Transoral Robotic Surgery, Leonard B. Kahn Head and Neck Cancer Institute at Atlantic Health System’s Morristown Medical Center and Carol G. Simon Cancer Center. He is one of the leaders of the Atlantic HPV Center.
During the COVID-19 pandemic, Moores Cancer Center at UC San Diego Health continues to offer potentially lifesaving treatment through cancer clinical trials.
Researchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Newly-completed series of patient guidelines from National Comprehensive Cancer Network (NCCN) shares expert advice with patients and caregivers on treatment and prevention for most common head and neck cancers, including some that are HPV-related.
Loss of an important tumor-suppressing gene allows head and neck cancer to spin off signals to nearby nerves, changing their function and recruiting them to the tumor, where they fuel growth and cancer progress.
Largest population-based analysis on factors that affect survival outcomes for HPV-positive oropharyngeal squamous cell carcinoma of the head and neck (SCCHN) find significant racial and socioeconomic disparities, according to new study in JNCCN-Journal of the National Comprehensive Cancer Network.
In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are located in the head and the neck.
APG-157 is made up of multiple compounds produced by plants, including curcumin. UCLA Jonsson Comprehensive Cancer Center researchers found that treatment with this botanical drug resulted in high concentrations of curcumin and its byproducts circulating in the blood and absorbed by tumor tissues within three hours after being taken orally.
Study shows Colorado drug SVC112 stops production of proteins that cancer stem cells need to survive and grow
A change in the tumor metabolism due to tobacco exposure could open new treatment avenues in head and neck cancer.